A Rare Case Resistant Chemotherapy Thymoma B2 Type, New Approach

Abstract

Invasive thymomas and thymic carcinomas are relatively rare tumors, which together represent about 0.2% to 1.5% of all malignancies. The majority of thymomas (90%) are found in the anterosuperior mediastinum. Type B2 thymoma, one of the rarest cases, was diagnosed in a 35-year-old male. Anamnesis, imaging examination, serological and invasive procedures confirmed the diagnosis. In 2020, the patient was operated on with thymoma R0-resection. The patient showed no progression until July 2022, when a locoregional recurrence was detected. The patient received 6 cycles of chemotherapy, to which the tumor showed resistance. After 6 months, the patient started a treatment with tyrosine kinase inhibitor sunitinib. If a patient is diagnosed with thymoma B2 that does not respond to standard chemotherapy, the tumor can be accepted as an aggressive one requiring a change to a new treatment.

Keywords

• thymoma
• diagnosis
• treatment
• outcome